Compare ANNX & SCHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANNX | SCHL |
|---|---|---|
| Founded | 2011 | 1920 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Books |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 972.5M | 842.4M |
| IPO Year | 2020 | 1995 |
| Metric | ANNX | SCHL |
|---|---|---|
| Price | $5.79 | $40.51 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 1 |
| Target Price | $16.50 | ★ $40.00 |
| AVG Volume (30 Days) | ★ 2.2M | 733.4K |
| Earning Date | 05-11-2026 | 03-19-2026 |
| Dividend Yield | N/A | ★ 1.99% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.87 |
| Revenue | N/A | ★ $1,487,100,000.00 |
| Revenue This Year | N/A | $1.88 |
| Revenue Next Year | $16,320.74 | $4.05 |
| P/E Ratio | ★ N/A | $21.70 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.60 | $16.78 |
| 52 Week High | $7.18 | $43.39 |
| Indicator | ANNX | SCHL |
|---|---|---|
| Relative Strength Index (RSI) | 47.71 | 58.00 |
| Support Level | $4.79 | $27.31 |
| Resistance Level | $6.56 | $43.39 |
| Average True Range (ATR) | 0.29 | 1.52 |
| MACD | -0.06 | -0.10 |
| Stochastic Oscillator | 8.43 | 49.48 |
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.
Scholastic Corp is an American publishing and education media company that focuses on books and educational material for schools, teachers, parents, and children. It creates print, digital, and audiobooks, learning materials and programs, classroom magazines, and other products that support children's learning and reading both at home and at school. The company also owns rights to various books, including Harry Potter, Dog Man, and The Hunger Games among others. It has three reportable segments Children's Book Publishing and Distribution, Education Solutions, and International. The majority of its revenue is from the Children's Book Publishing and Distribution segment.